Prednisolon Pfizer may be available in the countries listed below.
Prednisolone is reported as an ingredient of Prednisolon Pfizer in the following countries:
International Drug Name Search
Risperidone Instasolv may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidone Instasolv in the following countries:
International Drug Name Search
Penipen may be available in the countries listed below.
Ampicillin is reported as an ingredient of Penipen in the following countries:
International Drug Name Search
Quinazil may be available in the countries listed below.
Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of Quinazil in the following countries:
International Drug Name Search
Generic Name: betamethasone and calcipotriene (topical) (BAY ta METH a sone and KAL si poe TRYE een)
Brand names: Taclonex, Taclonex Scalp, Dovobet
Betamethasone is a topical corticosteroid. It reduces swelling, relieves itching, and constricts blood vessels.
Calcipotriene is a form of vitamin D. It works by decreasing the rate of skin cell reproduction.
Betamethasone and calcipotriene is a combination drug used to treat psoriasis vulgaris.
Betamethasone and calcipotriene may also be used for other purposes not listed in this medication guide.
Use this medication exactly as it was prescribed for you. Do not use it in larger doses or for longer than recommended by your doctor.
Before using betamethasone and calcipotriene, tell your doctor if you are pregnant or breast-feeding.
If you miss a dose, use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not use extra medicine to make up the missed dose.
There may be other drugs that can affect betamethasone and calcipotriene. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
Less serious side effects are more likely, and you may have none at all. Talk to your doctor about any side effect that seems unusual or is especially bothersome.
Before using this medication, tell your doctor if you have:
low or high levels of calcium in your blood;
liver or kidney disease;
severe forms of psoriasis (with pus, skin peeling, severe redness); or
a skin infection.
If you have any of these conditions, you may not be able to use betamethasone and calcipotriene, or you may need a dose adjustment or special tests during treatment.
Tell your doctor if you are receiving UV light treatments (phototherapy) for your psoriasis.
Use betamethasone and calcipotriene exactly as it was prescribed for you. Do not use it in larger doses or for longer than recommended by your doctor.
This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.
Betamethasone and calcipotriene topical is for use on the skin only. However, do not apply the medicine to your face, underarms, or groin (genital area).
Apply a thin layer of the medication and rub it in completely.
While you are using this medication, your blood and urine may need to be tested on a regular basis. It is important that you not miss any scheduled visits to your doctor.
Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not use extra medicine to make up the missed dose.
Overdose symptoms may include nausea, vomiting, lost appetite, tiredness, trouble breathing, joint/muscle pain, feeling light-headed, or fainting.
Avoid applying this medicine to more than one-third of your skin surface at any one time.
severe skin irritation on treated areas;
worsened symptoms or no improvement in psoriasis;
pus, swelling, redness, increased itching, or other signs of skin infection;
confusion, thirst, extreme tiredness, lost appetite, weight loss;
adrenal insufficiency--nausea, vomiting, lost appetite, tiredness, trouble breathing, joint/muscle pain, feeling light-headed, fainting;
Cushing syndrome--weight gain (especially in your face), thinning muscles in your arms or legs, easy bruising, thinning skin, acne, increased facial hair, darkened skin; or
high blood sugar (hyperglycemia)--increased urination and thirst, nausea, vomiting.
Less serious side effects may include:
burning or mild itching;
red or scaly rash;
swollen hair follicles; or
changes in the color of treated skin areas.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Psoriasis:
betamethasone-calcipotriene topical ointment:
Psoriasis vulgaris: apply to the affected areas once daily for up to four weeks. The maximum weekly dose should not exceed 100 g.
betamethasone-calcipotriene topical suspension:
Psoriasis vulgaris of the scalp: apply to the affected areas once daily for 2 weeks or until cleared. Treatment may be continued for up to 8 weeks. The maximum weekly dose should not exceed 100 g.
Before using betamethasone and calcipotriene, tell your doctor if you are using any other steroid medicines, or other medicines to treat psoriasis.
There may be other drugs that can interact with betamethasone and calcipotriene. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: betamethasone and calcipotriene side effects (in more detail)
Pangest may be available in the countries listed below.
Bromopride is reported as an ingredient of Pangest in the following countries:
Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pangest in the following countries:
International Drug Name Search
Genlac may be available in the countries listed below.
Lactulose is reported as an ingredient of Genlac in the following countries:
International Drug Name Search
Retrovir AZT may be available in the countries listed below.
Zidovudine is reported as an ingredient of Retrovir AZT in the following countries:
International Drug Name Search
NB-3 may be available in the countries listed below.
Nicotinamide is reported as an ingredient of NB-3 in the following countries:
International Drug Name Search
Pinavérium Teva may be available in the countries listed below.
Pinaverium Bromide is reported as an ingredient of Pinavérium Teva in the following countries:
International Drug Name Search
L-Cetifilm may be available in the countries listed below.
Levocetirizine is reported as an ingredient of L-Cetifilm in the following countries:
International Drug Name Search
Dicicloverina may be available in the countries listed below.
Dicicloverina (DCIT) is also known as Dicycloverine (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Relieving congestion and cough due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.
Detussin Liquid is a decongestant and cough suppressant combination. It works by constricting blood vessels and reducing swelling in the nasal passages. This allows you to breathe more easily. The cough suppressant works in the brain to decrease the cough reflex to help decrease a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Detussin Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Detussin Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Detussin Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Detussin Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Detussin Liquid.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; drowsiness, excitability; headache; nausea; nervousness or anxiety; trouble sleeping; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; tremor.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Detussin side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Detussin Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Detussin Liquid out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Detussin Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
NOT FOR USE IN NEONATES
CONTAINS BENZYL ALCOHOL
Rx ONLY
Doxapram Hydrochloride Injection USP, is a clear, colorless, sterile, non-pyrogenic, aqueous solution with pH 3.5 to 5, for intravenous administration.
Each mL contains Doxapram hydrochloride 20 mg, benzyl alcohol (as preservative) 0.9%, and water for injection, q.s.
Doxapram is a respiratory stimulant.
Doxapram hydrochloride is a white to off-white, crystalline powder, sparingly soluble in water, alcohol and chloroform. It has the following chemical structure and name:
Molecular Formula: C24H30N2O2•HCl•H2O M. W. = 432.98
(±)-1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate.
Doxapram hydrochloride produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. As the dosage level is increased, the central respiratory centers in the medulla are stimulated with progressive stimulation of other parts of the brain and spinal cord.
The onset of respiratory stimulation following the recommended single intravenous injection of Doxapram hydrochloride usually occurs in 20 to 40 seconds with peak effect at 1 to 2 minutes. The duration of effect may vary from 5 to 12 minutes.
The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate.
A pressor response may result following Doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following Doxapram administration, an increased release of catecholamines has been noted.
Although opiate-induced respiratory depression is antagonized by Doxapram, the analgesic effect is not affected.
Doxapram is metabolized via ring hydroxylation to ketoDoxapram, an active metabolite readily detected in the plasma.
a. When the possibility of airway obstruction and/or hypoxia have been eliminated, Doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs.
b. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.)
Exercising care to prevent vomiting and aspiration, Doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage.
Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE AND ADMINISTRATION) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen.
It should not be used in conjunction with mechanical ventilation.
Doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components.
Doxapram should not be used in patients with epilepsy or other convulsive disorders.
Doxapram is contraindicated in patients with proven or suspected pulmonary embolism.
Doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle paresis (including neuromuscular blockade), flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis, or other conditions resulting in restriction of the chest wall, muscles of respiration, or alveolar expansion.
Doxapram is contraindicated in patients with evidence of head injury, cerebral vascular accident, or cerebral edema, and in those with significant cardiovascular impairment, uncompensated heart failure, severe coronary artery disease, or severe hypertension, including that associated with hyperthyroidism or pheochromocytoma. (See WARNINGS.)
Doxapram should not be used in conjunction with mechanical ventilation.
Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources. (See PRECAUTIONS, Pediatric Use. )
a. Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. More specific tests (e.g., peripheral nerve stimulation, airway pressures, head lift, pulse oximetry, and end-tidal carbon dioxide) to assess adequacy of ventilation are recommended before administering Doxapram.
b. Doxapram should be administered with great care and only under careful supervision to patients with hypermetabolic states such as hyperthyroidism or pheochromocytoma.
c. Since narcosis may recur after stimulation with Doxapram, care should be taken to maintain close observation until the patient has been fully alert for 1/2 to 1 hour.
d. In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of Doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation (see PRECAUTIONS, Drug Interactions ).
Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques.
Because of the associated increased work of breathing, do not increase the rate of infusion of Doxapram in severely ill patients in an attempt to lower pCO2.
a. An adequate airway is essential and airway protection should be considered since Doxapram may stimulate vomiting.
b. Recommended dosages of Doxapram should be employed and maximum total dosages should not be exceeded. In order to avoid side effects, it is advisable to use the minimum effective dosage.
c. Monitoring of the blood pressure, pulse rate, and deep tendon reflexes is recommended to prevent overdosage.
d. Vascular extravasation or use of a single injection site over an extended period should be avoided since either may lead to thrombophlebitis or local skin irritation.
e. Rapid infusion may result in hemolysis.
f. Lowered pCO2 induced by hyperventilation produces cerebral vasoconstriction and slowing of the cerebral circulation. This should be taken into consideration on an individual basis. In certain patients a pressor effect of Doxapram on the pulmonary circulation may result in a fall of the arterial pO2 probably due to a worsening of ventilation perfusion-matching in the lungs despite an overall improvement in alveolar ventilation and a fall in pCO2. Patients should be carefully supervised taking into account available blood gas measurements.
g. There is a risk that Doxapram will produce adverse effects (including seizures) due to general central nervous system stimulation. Muscle involvement may range from fasciculation to spasticity. Anticonvulsants such as intravenous short-acting barbiturates, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-hyperventilation or hypoventilation.
h. Doxapram should be administered cautiously to patients receiving sympathomimetic or monoamine oxidase inhibiting drugs, since an additive pressor effect may occur.
i. Blood pressure increases are generally modest but significant increases have been noted in some patients. Because of this, Doxapram is not recommended for use in patients with severe hypertension (see CONTRAINDICATIONS).
j. Cardiovascular effects may include various dysrhythmias. Patients receiving Doxapram should be monitored for disturbance of their cardiac rhythm.
k. If sudden hypotension or dyspnea develops, Doxapram should be stopped.
l. Doxapram should be administered with caution to patients with significantly impaired hepatic or renal function as a reduction in the rate of metabolism or excretion of metabolites may alter the response.
a. The same consideration to pre-existing disease states should be exercised as in non-anesthetized individuals. See CONTRAINDICATIONS and WARNINGS covering use in hypertension, asthma, disturbances of respiratory mechanics including airway obstruction, CNS disorders including increased cerebrospinal fluid pressure, convulsive disorders, acute agitation, and profound metabolic disorders.
b. See PRECAUTIONS, Drug Interactions.
a. Arrhythmias seen in some patients in acute respiratory failure secondary to chronic obstructive pulmonary disease are probably the result of hypoxia. Doxapram should be used with caution in these patients.
b. Arterial blood gases should be drawn prior to the initiation of Doxapram infusion and oxygen administration, then at least every 1/2 hour during the infusion period to prevent development of CO2 retention and acidosis in patients with chronic obstructive pulmonary disease with acute hypercapnia. Doxapram administration does not diminish the need for careful monitoring of the patient or the need for supplemental oxygen in patients with acute respiratory failure. Doxapram should be stopped if the arterial blood gases deteriorate, and mechanical ventilation should be initiated.
Administration of Doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General).
In patients who have received neuromuscular blocking agents, Doxapram may temporarily mask the residual effects of these drugs.
In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of Doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation (see WARNINGS).
There may be an interaction between Doxapram and aminophylline and between Doxapram and theophylline manifested by increased skeletal muscle activity, agitation, and hyperactivity.
No carcinogenic or mutagenic studies have been performed using Doxapram. Doxapram did not adversely affect the breeding performance of rats.
Reproduction studies have been performed in rats at doses up to 1.6 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Doxapram. There are, however, no adequate and well-controlled studies in pregnant women. Because the animals in the reproduction studies were dosed by the IM and oral routes and animal reproduction studies, in general, are not always predictive of human response, this drug should be used during pregnancy only it clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Doxapram hydrochloride is administered to a nursing woman.
Safety and effectiveness in pediatric patients below the age of 12 years have not been established. This product contains benzyl alcohol as a preservative. Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The “gasping syndrome”, (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.
Premature neonates given Doxapram have developed hypertension, irritability, jitteriness, hyperglycemia, glucosuria, abdominal distension, increased gastric residuals, vomiting, bloody stools, necrotizing enterocolitis, erratic limb movements, excessive crying, disturbed sleep, premature eruption of teeth, and QT prolongation that has resulted in heart block. In premature neonates with risk factors such as a previous seizure, perinatal asphyxia, or intracerebral hemorrhage, seizures have occurred. In many instances, Doxapram was administered following administration of xanthine derivatives such as caffeine, aminophyline or theophylline.
Adverse reactions reported coincident with the administration of Doxapram include:
Symptoms of overdosage are extensions of the pharmacologic effects of the drug. Excessive pressor effect, such as hypertension, tachycardia, skeletal muscle hyperactivity, and enhanced deep tendon reflexes may be early signs of overdosage. Therefore, the blood pressure, pulse rate and deep tendon reflexes should be evaluated periodically and the dosage or infusion rate adjusted accordingly.
Other effects may include agitation, confusion, sweating, cough, and dyspnea.
Convulsive seizures are unlikely at recommended dosages. In unanesthetized animals, the convulsant dose is 70 times greater than the respiratory stimulant dose. Intravenous LD50 values in the mouse and rat were approximately 75 mg/kg and in the cat and dog were 40 to 80 mg/kg.
Except for management of chronic obstructive pulmonary disease associated with acute hypercapnia, the maximum recommended dosage is 3 GRAMS/24 HOURS. (See DOSAGE AND ADMINISTRATION.)
There is no specific antidote for Doxapram. Management should be symptomatic. Anticonvulsants, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-hyperventilation or hypoventilation.
There is no evidence that Doxapram is dialyzable; further, the half-life of Doxapram makes it unlikely that dialysis would be appropriate in managing overdose with this drug.
NOTE: CONTAINS BENZYL ALCOHOL (SEE PRECAUTIONS)
| Recommended | Maximum dose per | Maximum | |
| Dosage | single injection | total dose * | |
| I.V. | |||
| Administration | mg/kg | mg/kg | mg/kg |
| |||
| Single Injection | 0.5-1 | 1.5 | 1.5 |
| Repeat Injections (5 min. intervals) | 0.5-1 | 1.5 | 2 |
| Infusion | 0.5-1 | — | 4 |
(See Table I. Dosage for postanesthetic use (I.V. and infusion. )
The recommended dose for I.V. administration is 0.5 to 1 mg/kg for a single injection and at 5-minute intervals. Careful observation of the patient during administration and for some time subsequently are advisable. The maximum total dosage by I.V. injection is 2 mg/kg.
The solution is prepared by adding 250 mg of Doxapram (12.5 mL) to 250 mL of dextrose 5% or 10% in water or normal saline solution. The infusion is initiated at a rate of approximately 5 mg/minute until a satisfactory respiratory response is observed, and maintained at a rate of 1 to 3 mg/minute. The rate of infusion should be adjusted to sustain the desired level of respiratory stimulation with a minimum of side effects. The maximum total dosage by infusion is 4 mg/kg, or approximately 300 mg for the average adult.
(See Table II. Dosage for drug-induced CNS depression. )
| ||
| METHOD ONE | METHOD TWO | |
| Priming dose single/repeat | Rate of intermittent | |
| I.V. injection | I.V. infusion | |
| Level of Depression | ||
| mg/kg | mg/kg/hr | |
| Mild * | 1 | 1-2 |
| Moderate † | 2 | 2-3 |
a. Give priming dose of 2 mg/kg body weight and repeat in 5 minutes. The priming dose for moderate depression is 2 mg/kg and the priming dose for mild depression is 1 mg/kg.
b. Repeat same dose q1 to 2h until patient wakens. Watch for relapse into unconsciousness or development of respiratory depression, since Doxapram does not affect the metabolism of CNS-depressant drugs.
c. If relapse occurs, resume injections q1 to 2h until arousal is sustained, or total maximum daily dose (3 grams) is given. After maximum dose has been given (3 grams), allow patient to sleep until 24 hours have elapsed from first injection of Doxapram, using assisted or automatic respiration if necessary.
d. Repeat procedure the following day until patient breathes spontaneously and sustains desired level of consciousness, or until maximum dosage (3 grams) is given.
e. Repetitive doses should be administered only to patients who have shown response to the initial dose.
f. Failure to respond appropriately indicates the need for neurologic evaluation for a possible central nervous system source of sustained coma.
a. Give priming dose as in Method One.
b. If patient wakens, watch for relapse; if no response, continue general supportive treatment for 1 to 2 hours and repeat priming dose of Doxapram. If some respiratory stimulation occurs, prepare I.V. infusion by adding 250 mg of Doxapram (12.5 mL) to 250 mL of saline or dextrose solution. Deliver at rate of 1 to 3 mg/min (60 to 180 mL/hr) according to size of patient and depth of coma. Discontinue Doxapram if patient begins to waken or at end of 2 hours.
c. Continue supportive treatment for 1/2 to 2 hours and repeat Step b.
d. Do not exceed 3 grams/day.
a. One vial of Doxapram (400 mg) should be mixed with 180 mL of dextrose 5% or 10% or normal saline solution (concentration of 2 mg/mL). The infusion should be started at 1 to 2 mg/minute (1/2 to 1 mL/minute); if indicated, increase to a maximum of 3 mg/minute. Arterial blood gases should be determined prior to the onset of Doxapram’s administration and at least every half hour during the two hours of infusion to insure against the insidious development of CO2-RETENTION AND ACIDOSIS. Alteration of oxygen concentration or flow rate may necessitate adjustment in the rate of Doxapram infusion.
b. Predictable blood gas patterns are more readily established with a continuous infusion of Doxapram. If the blood gases show evidence of deterioration, the infusion of Doxapram should be discontinued.
c. ADDITIONAL INFUSIONS BEYOND THE SINGLE MAXIMUM TWO HOUR ADMINISTRATION PERIOD ARE NOT RECOMMENDED.
Doxapram hydrochloride is compatible with 5% and 10% dextrose in water or normal saline.
ADMIXTURE OF Doxapram WITH ALKALINE SOLUTIONS SUCH AS 2.5% THIOPENTAL SODIUM, SODIUM BICARBONATE, FUROSEMIDE, OR AMINOPHYLLINE WILL RESULT IN PRECIPITATION OR GAS FORMATION.
Doxapram is also not compatible with ascorbic acid, cefoperazone sodium, cefotaxime sodium, cefotetan sodium, cefuroxime sodium, folic acid, dexamethasone disodium phosphate, diazepam, hydrocortisone sodium phosphate, methylprednisolone sodium, or hydrocortisone sodium succinate.
Admixture of Doxapram and ticarcillin disodium results in an 18% loss of Doxapram in 3 hours. When Doxapram is mixed with minocycline hydrochloride, there is a loss of 8% of Doxapram in 3 hours and a 13% loss of Doxapram in 6 hours.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Doxapram Hydrochloride Injection USP, is available in 20 mL multiple dose vials containing 20 mg of Doxapram hydrochloride per mL with benzyl alcohol 0.9% as the preservative (NDC55390-035-01); individually boxed.
Store at 20° to 25°C (68° and 77°F). See USP Controlled Room Temperature.
Manufactured for; Manufactured by:
Bedford Laboratories™ Ben Venue Laboratories, Inc.
Bedford, OH 44146 Bedford, OH 44146
March 2007 DXP - P02
Vial Label 400 mg/20 mL
Unit Carton 400 mg/20 mL
| Doxapram HYDROCHLORIDE Doxapram hydrochloride injection | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA076266 | 02/10/2003 | |
| Labeler - Bedford Laboratories (884528407) |
Dirozyl may be available in the countries listed below.
Metronidazole is reported as an ingredient of Dirozyl in the following countries:
International Drug Name Search
Levoquin may be available in the countries listed below.
Levofloxacin is reported as an ingredient of Levoquin in the following countries:
International Drug Name Search
Co-Inhibace may be available in the countries listed below.
Cilazapril monohydrate (a derivative of Cilazapril) is reported as an ingredient of Co-Inhibace in the following countries:
Hydrochlorothiazide is reported as an ingredient of Co-Inhibace in the following countries:
International Drug Name Search
Mucodos may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Mucodos in the following countries:
International Drug Name Search
Tobramin may be available in the countries listed below.
Tobramycin sulfate (a derivative of Tobramycin) is reported as an ingredient of Tobramin in the following countries:
International Drug Name Search
Omeman may be available in the countries listed below.
Omeprazole is reported as an ingredient of Omeman in the following countries:
International Drug Name Search
In the US, Zyvox (linezolid systemic) is a member of the drug class miscellaneous antibiotics and is used to treat Bacteremia, Methicillin-Resistant Staphylococcus Aureus Infection, Nosocomial Pneumonia, Pneumonia and Skin and Structure Infection.
US matches:
UK matches:
Linezolid is reported as an ingredient of Zyvox in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Lantelol may be available in the countries listed below.
Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Lantelol in the following countries:
International Drug Name Search
Torasemida Winthrop may be available in the countries listed below.
Torasemide is reported as an ingredient of Torasemida Winthrop in the following countries:
International Drug Name Search
Demeclociclina may be available in the countries listed below.
Demeclociclina (DCIT) is known as Demeclocycline in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Oxsoralen Lotion is powerful and could produce severe burns if improperly used. Oxsoralen Lotion must never be dispensed to a patient. A doctor using special light conditions must apply Oxsoralen Lotion.
Treating vitiligo in combination with controlled doses of ultraviolet A (UVA) or sunlight. It may also be used for other conditions as determined by your doctor.
Oxsoralen Lotion is a psoralen used in combination with light therapy. It works by making the skin more sensitive to UV light. It appears that this sensitivity results in damage to the skin cells when UV light treatment is given. Damaged skin cells grow more slowly and the rate of tissue growth is reduced.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Oxsoralen Lotion. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Oxsoralen Lotion. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Oxsoralen Lotion may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Oxsoralen Lotion as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Oxsoralen Lotion.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dryness or redness of the skin; itching.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blistering; burns on the treated area from overexposure to UVA or sunlight; severe swelling or redness of the skin; swelling of the feet or lower legs; tenderness.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Oxsoralen side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blisters; burns. Oxsoralen Lotion may be harmful if swallowed.
Oxsoralen Lotion is usually handled and stored by a health care provider. If you are using Oxsoralen Lotion at home, store Oxsoralen Lotion as directed by your pharmacist or health care provider. Keep Oxsoralen Lotion out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Oxsoralen Lotion. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Diphenal may be available in the countries listed below.
Phenobarbital is reported as an ingredient of Diphenal in the following countries:
Phenytoin sodium salt (a derivative of Phenytoin) is reported as an ingredient of Diphenal in the following countries:
International Drug Name Search
Definition of Pelvic Inflammatory Disease: An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections.
The following drugs and medications are in some way related to, or used in the treatment of Pelvic Inflammatory Disease. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Harvard Health Guide:
There are currently no drugs listed for "Thromboangiitis Obliterans".
Definition of Thromboangiitis Obliterans: Thromboangiitis obliterans is a disease that causes obstruction of the blood vessels of the hands and feet. More...
Micromedex Care Notes:
Medical Encyclopedia:
Nozlen may be available in the countries listed below.
Sodium Gualenate is reported as an ingredient of Nozlen in the following countries:
International Drug Name Search
Rec.INN
0122312-55-4
C28-H60-Al14-O71-S7
2134
Antacid
[μ₇-[[diosmin heptasulfato](7-)]]tetracontahydroxytetradecaaluminium (WHO)
[μ₇-[7-[[6-O-[6-Deoxy-2,3,4-tri-O-(sulfo-κO)-α-L-mannopyranosyl]-2,3,4-tri-O-(sulfo-κO)-ß-D-glucopyranosyl]oxy]-5-hydroxy-2-[4-methoxy-3-[(sulfo-κO)oxy]pheny]-4-H-1-benzopyran-4-onato(7-)]]tetradeca-μ-hydroxyheneicosahydroxytetradecaaluminium
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Bromazepam CF may be available in the countries listed below.
Bromazepam is reported as an ingredient of Bromazepam CF in the following countries:
International Drug Name Search
Winthrop Oxaliplatin may be available in the countries listed below.
Oxaliplatin is reported as an ingredient of Winthrop Oxaliplatin in the following countries:
International Drug Name Search
Clonazépam may be available in the countries listed below.
Clonazépam (DCF) is known as Clonazepam in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Neupram may be available in the countries listed below.
Haloperidol is reported as an ingredient of Neupram in the following countries:
International Drug Name Search
Chlorothiazide Sodium (USAN) is known as Chlorothiazide in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
Histaclar may be available in the countries listed below.
Loratadine is reported as an ingredient of Histaclar in the following countries:
International Drug Name Search
Altavit may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfamethoxazole is reported as an ingredient of Altavit in the following countries:
Trimethoprim is reported as an ingredient of Altavit in the following countries:
International Drug Name Search
